Yes absolutely. If a company wants to partner (rather than acquire) Neuren they need to license NNZ-2591 in its entirety and it will cost them. The deal would also not be so back ended. Given those requirements, someone looking for NNZ-2591 may as well take out the entire company and get exposure to RTT. The deal that Acadia did seemed prudent for them at the time, but has ended up costing them more over the long run. The opposite will happen for NNZ-2591.
Jon also commented on the fact the Acadia deal exists isn't a problem or a friction point. They have RTT and FXS for 2591 and that is it, and it wouldn't be a barrier to any transaction as far as I can tell.
The fact we're back in the $12 range is mind blogging. I am just going to close my trading screen and forget about it.
NEU Price at posting:
$12.94 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)